PACB
Pacific Biosciences of California, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.34
+3.08%Year over year
Reported trailing growth
- Revenue
- +2.0%
- EBITDA
- +2.7%
- EBIT
- +76.5%
- EPS
- +76.0%
- Free cash flow
- -8.8%
- Operating cash flow
- -8.8%
Forward estimates
Based on analyst estimates
- Revenue
- +6.1%
- EBITDA
- -24.7%
- EPS
- -16.7%
Three-year CAGR
- Revenue
- +7.6%
- EBITDA
- +85.9%
- EBIT
- -17.6%
- Net income
- -76.3%
- EPS
- -61.1%
- Free cash flow
- +46.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026